Liheng Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liheng Guo has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Minzhou Zhang
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
4 shared publications - Rui-Xiang Zeng
Center for Dyslipidemia and Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No 167 BeiLiShi Road, XiCheng District, Beijing 100037, China
4 shared publications Min-Zhou Zhang
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
3 shared publicationsXin Yin
Department of Intensive Care Unit, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China
3 shared publications- Biao Cai
Emergency Department, The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, China
2 shared publications - Lu Jiang
The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
2 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Springer Nature in Critical Care
Efficacy and safety of shenfu injection on sepsis: a systematic review and meta-analysis
- 12 November 2026
- Published by Springer Nature in Critical Care
Open AccessEfficacy and safety of shenfu injection on sepsis: a systematic review and meta-analysis
- Open Access
- 7 March 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Clinical efficacy and safety of recombinant human brain natriuretic peptide in the treatment of sepsis complicated by heart failure: a systematic review and meta-analysis
Heart failure is among the most prevalent organ dysfunctions in sepsis and carries a high mortality rate. Currently, no specific drugs are available. Recom
- 7 March 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Open AccessClinical efficacy and safety of recombinant human brain natriuretic peptide in the treatment of sepsis complicated by heart failure: a systematic review and meta-analysis
Heart failure is among the most prevalent organ dysfunctions in sepsis and carries a high mortality rate. Currently, no specific drugs are available. Recom
- Open Access
- 13 September 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1393137
Associations of total protein, albumin, and globulin with insulin resistance: an NHANES study
Objective: Insulin resistance (IR) is a well-established major risk factor for type 2 diabetes mellitus, nonalcoholic fatty liver disease, and atherosclerotic cardiovascular disease. Previous studies have shown an association between increased serum albumin (ALB) levels and the risk of IR. However, there is a lack of studies simultaneously evaluating the association of total protein (TP), ALB, and globulin (GLB) with IR.Methods: A total of 14,828 individuals (average age 49 ± 18 years) with complete data from the National Health and Nutrition Examination Survey (NHANES) were enrolled and divided into two groups (non-IR group, n = 8,653 and IR group, n = 6,175). Spearman’s correlation analysis, multivariable logistic regression models, restricted cubic spline curves, and subgroup analysis were performed to explore those associations.Results: After adjustment for potential confounders, multivariable logistic regression analysis revealed that scaled per 10g/L increment, the fully adjusted odds ratios (ORs) (95% confidence interval (CI)) for IR prevalence were 1.54 (95% CI 1.41-1.69, P < 0.0001), 1.09 (95% CI 0.95-1.25), P = 0.1995), and 1.62 (95% CI 1.47-1.79, P < 0.0001) for TP, ALB, and GLB respectively. Compared to those in the lowest quantiles, the prevalence of IR in subjects in the highest TP and GLB quantiles was 2.06 and 1.91 times, respectively. Furthermore, restrictive cubic curves confirmed that the relationship of TP, ALB, and GLB with IR prevalence was a linear relationship.Conclusions: The present cross-sectional study, for the first time, provided supportive evidence of positive associations of TP and GLB with IR, but not ALB, and demonstrated that TP and GLB might be useful markers for IR prevalence.
- 13 September 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1393137
Open AccessAssociations of total protein, albumin, and globulin with insulin resistance: an NHANES study
Objective: Insulin resistance (IR) is a well-established major risk factor for type 2 diabetes mellitus, nonalcoholic fatty liver disease, and atherosclerotic cardiovascular disease. Previous studies have shown an association between increased serum albumin (ALB) levels and the risk of IR. However, there is a lack of studies simultaneously evaluating the association of total protein (TP), ALB, and globulin (GLB) with IR.Methods: A total of 14,828 individuals (average age 49 ± 18 years) with complete data from the National Health and Nutrition Examination Survey (NHANES) were enrolled and divided into two groups (non-IR group, n = 8,653 and IR group, n = 6,175). Spearman’s correlation analysis, multivariable logistic regression models, restricted cubic spline curves, and subgroup analysis were performed to explore those associations.Results: After adjustment for potential confounders, multivariable logistic regression analysis revealed that scaled per 10g/L increment, the fully adjusted odds ratios (ORs) (95% confidence interval (CI)) for IR prevalence were 1.54 (95% CI 1.41-1.69, P < 0.0001), 1.09 (95% CI 0.95-1.25), P = 0.1995), and 1.62 (95% CI 1.47-1.79, P < 0.0001) for TP, ALB, and GLB respectively. Compared to those in the lowest quantiles, the prevalence of IR in subjects in the highest TP and GLB quantiles was 2.06 and 1.91 times, respectively. Furthermore, restrictive cubic curves confirmed that the relationship of TP, ALB, and GLB with IR prevalence was a linear relationship.Conclusions: The present cross-sectional study, for the first time, provided supportive evidence of positive associations of TP and GLB with IR, but not ALB, and demonstrated that TP and GLB might be useful markers for IR prevalence.
- 8 December 2023
- Published by Elsevier in Heart & Lung
- Vol. 64, 93-99
Prognostic value of hemoglobin in patients with sepsis: A systematic review and meta-analysis
- 8 December 2023
- Published by Elsevier in Heart & Lung
- Vol. 64, 93-99
Prognostic value of hemoglobin in patients with sepsis: A systematic review and meta-analysis
- Open Access
- 30 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2615
Relationship of Glycated Hemoglobin A1c with All-Cause and Cardiovascular Mortality among Patients with Hypertension
Both low and high glycated hemoglobin A1c (HbA1c) levels are well-established causal risk factors for all-cause and cardiovascular mortality in the general population and diabetic patients. However, the relationship between HbA1c with all-cause and cardiovascular mortality among patients with hypertension is unclear. We used NHANES data from 1999 to 2014 as the basis for this population-based cohort study. Based on HbA1c levels (HbA1c > 5, HbA1c > 5.5, HbA1c > 6, HbA1c > 6.5, HbA1c > 7%), hypertensive patients were divided into five groups. An analysis of multivariable Cox proportional hazards was conducted based on hazard ratios (HRs) and respective 95% confidence intervals (CIs). The relationship between HbA1c and mortality was further explored using Kaplan–Meier survival curves, restricted cubic spline curves, and subgroup analyses. In addition, 13,508 patients with hypertension (average age 58.55 ± 15.56 years) were included in the present analysis, with 3760 (27.84%) all-cause deaths during a follow-up of 127.69 ± 57.9 months. A U-shaped relationship was found between HbA1c and all-cause and cardiovascular mortality (all p for likelihood ratio tests were 0.0001). The threshold value of HbA1c related to the lowest risk for all-cause and cardiovascular mortality was 5.3% and 5.7%, respectively. Below the threshold value, increased HbA1c levels reduced the risk of all-cause mortality (HR 0.68, 95% CI 0.51–0.90, p = 0.0078) and cardiovascular mortality (HR 0.77, 95% CI 0.57–1.05, p = 0.0969). Inversely, above the threshold value, increased HbA1c levels accelerated the risk of all-cause mortality (HR 1.14, 95% CI 1.11–1.18, p < 0.0001) and cardiovascular mortality (HR 1.22, 95% CI 1.16–1.29, p < 0.0001). In conclusion, A U-shape relationship was observed between HbA1c and all-cause and cardiovascular mortality among hypertensive patients.
- 30 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2615
Open AccessRelationship of Glycated Hemoglobin A1c with All-Cause and Cardiovascular Mortality among Patients with Hypertension
Both low and high glycated hemoglobin A1c (HbA1c) levels are well-established causal risk factors for all-cause and cardiovascular mortality in the general population and diabetic patients. However, the relationship between HbA1c with all-cause and cardiovascular mortality among patients with hypertension is unclear. We used NHANES data from 1999 to 2014 as the basis for this population-based cohort study. Based on HbA1c levels (HbA1c > 5, HbA1c > 5.5, HbA1c > 6, HbA1c > 6.5, HbA1c > 7%), hypertensive patients were divided into five groups. An analysis of multivariable Cox proportional hazards was conducted based on hazard ratios (HRs) and respective 95% confidence intervals (CIs). The relationship between HbA1c and mortality was further explored using Kaplan–Meier survival curves, restricted cubic spline curves, and subgroup analyses. In addition, 13,508 patients with hypertension (average age 58.55 ± 15.56 years) were included in the present analysis, with 3760 (27.84%) all-cause deaths during a follow-up of 127.69 ± 57.9 months. A U-shaped relationship was found between HbA1c and all-cause and cardiovascular mortality (all p for likelihood ratio tests were 0.0001). The threshold value of HbA1c related to the lowest risk for all-cause and cardiovascular mortality was 5.3% and 5.7%, respectively. Below the threshold value, increased HbA1c levels reduced the risk of all-cause mortality (HR 0.68, 95% CI 0.51–0.90, p = 0.0078) and cardiovascular mortality (HR 0.77, 95% CI 0.57–1.05, p = 0.0969). Inversely, above the threshold value, increased HbA1c levels accelerated the risk of all-cause mortality (HR 1.14, 95% CI 1.11–1.18, p < 0.0001) and cardiovascular mortality (HR 1.22, 95% CI 1.16–1.29, p < 0.0001). In conclusion, A U-shape relationship was observed between HbA1c and all-cause and cardiovascular mortality among hypertensive patients.
- Open Access
- 9 November 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1041326
Effects of combination therapy with Shenfu Injection in critically ill patients with septic shock receiving mechanical ventilation: A multicentric, real-world study
Background:Septic shock has increasingly become a cause of death threatening human survival. Shenfu Injection (SFI), a patented Chinese medicine, has been widely used in the treatment of patients with sepsis and cardiovascular diseases domestically. We sought to examine whether combination therapy with SFI can improve clinical outcomes in critically ill patients undergoing mechanical ventilation (MV).Methods:This real-world, multicenter retrospective trial enrolled consecutive adult patients with sepsis requiring MV from four medical/surgical intensive care units (ICUs) in China between August 2016 and September 2021. Patients were identified from the medical information department database of each center and assigned to either of two groups (SFI or control) on the basis of the initial treatment received. The primary outcome was 28-day all-cause mortality, and the durations of vasopressor therapy and MV, the ICU length of stay, and costs were assessed as secondary outcomes. Subsequently, we performed a meta-analysis of randomized controlled trials (RCTs) on SFI published before July 2021 to verify our conclusions.Results:2311 mechanically ventilated patients with septic shock (1128 patients in the SFI group and 1183 in the control group) were analyzed. The survival probability during the first 28 days after admission in the SFI group was greater than that in the control group [p< 0.01 by log-rank test; hazard ratio (HR), 0.56; 95% confidence interval (CI), 0.39–0.72]. Patients in the SFI group also experienced a significantly reduced duration of vasopressor therapy [7.28 (95% CI, 6.14–8.42)vs.12.06 (95% CI, 10.71–13.41) days,p< 0.001], more ventilator-free days [6.49 (95% CI, 5.42–7.55)vs.10.84 (95% CI, 9.59–12.09) days,p< 0.001], a shorter ICU length of stay [18.48 (95% CI, 17.59–19.38)vs.23.77 (95% CI, 22.47–25.07) days,p< 0.001], and more time free from organ failure [14.23 (95% CI, 12.94–15.52)vs.19.07 (95% CI, 16.09–22.05) days,p< 0.001]. No major adverse effects were reported in either group.Conclusion:Among critically ill patients requiring MV, combination therapy with SFI can improve the survival probability without any obvious adverse reactions.
- 9 November 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1041326
Open AccessEffects of combination therapy with Shenfu Injection in critically ill patients with septic shock receiving mechanical ventilation: A multicentric, real-world study
Background:Septic shock has increasingly become a cause of death threatening human survival. Shenfu Injection (SFI), a patented Chinese medicine, has been widely used in the treatment of patients with sepsis and cardiovascular diseases domestically. We sought to examine whether combination therapy with SFI can improve clinical outcomes in critically ill patients undergoing mechanical ventilation (MV).Methods:This real-world, multicenter retrospective trial enrolled consecutive adult patients with sepsis requiring MV from four medical/surgical intensive care units (ICUs) in China between August 2016 and September 2021. Patients were identified from the medical information department database of each center and assigned to either of two groups (SFI or control) on the basis of the initial treatment received. The primary outcome was 28-day all-cause mortality, and the durations of vasopressor therapy and MV, the ICU length of stay, and costs were assessed as secondary outcomes. Subsequently, we performed a meta-analysis of randomized controlled trials (RCTs) on SFI published before July 2021 to verify our conclusions.Results:2311 mechanically ventilated patients with septic shock (1128 patients in the SFI group and 1183 in the control group) were analyzed. The survival probability during the first 28 days after admission in the SFI group was greater than that in the control group [p< 0.01 by log-rank test; hazard ratio (HR), 0.56; 95% confidence interval (CI), 0.39–0.72]. Patients in the SFI group also experienced a significantly reduced duration of vasopressor therapy [7.28 (95% CI, 6.14–8.42)vs.12.06 (95% CI, 10.71–13.41) days,p< 0.001], more ventilator-free days [6.49 (95% CI, 5.42–7.55)vs.10.84 (95% CI, 9.59–12.09) days,p< 0.001], a shorter ICU length of stay [18.48 (95% CI, 17.59–19.38)vs.23.77 (95% CI, 22.47–25.07) days,p< 0.001], and more time free from organ failure [14.23 (95% CI, 12.94–15.52)vs.19.07 (95% CI, 16.09–22.05) days,p< 0.001]. No major adverse effects were reported in either group.Conclusion:Among critically ill patients requiring MV, combination therapy with SFI can improve the survival probability without any obvious adverse reactions.
- 24 October 2022
- Published by Elsevier in Life Sciences
- Vol. 310, 121123
Astragaloside IV ameliorates sepsis-induced myocardial dysfunction by regulating NOX4/JNK/BAX pathway
- 24 October 2022
- Published by Elsevier in Life Sciences
- Vol. 310, 121123
Astragaloside IV ameliorates sepsis-induced myocardial dysfunction by regulating NOX4/JNK/BAX pathway
- Open Access
- 19 September 2022
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 60 (1) , 1812-1818
The BCL2/BAX/ROS pathway is involved in the inhibitory effect of astragaloside IV on pyroptosis in human umbilical vein endothelial cells
Astragaloside IV (AS-IV) is extracted from Astragalus membranaceus (Fisch.) Bunge (Fabaceae). However, its effects on endothelial cell injury remain unclear.To investigate the mechanisms underlying...
- 19 September 2022
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 60 (1) , 1812-1818
Open AccessThe BCL2/BAX/ROS pathway is involved in the inhibitory effect of astragaloside IV on pyroptosis in human umbilical vein endothelial cells
Astragaloside IV (AS-IV) is extracted from Astragalus membranaceus (Fisch.) Bunge (Fabaceae). However, its effects on endothelial cell injury remain unclear.To investigate the mechanisms underlying...
- Open Access
- 23 August 2019
- Published by JMIR Publications Inc. in JMIR Preprints
The effect of Baduanjin sequential therapy on the quality of life and cardiac function in patients with acute myocardial infarction after percutaneous coronary intervention:A randomized controlled trial (Preprint)
BACKGROUND Acute myocardial infarction (AMI) is a serious type of coronary artery disease (CAD) with the potential for substantial morbidity and mortalit. Percutaneous coronary intervention (PCI) is an effective treatment. However, most patients still suffer from angina pectoris, anxiety, depression and reduced cardiac function after PCI. OBJECTIVE The purpose of this study was to examine the effects of Baduanjin sequential therapy (BST) on the quality of life and cardiac function in patients with AMI after PCI. METHODS The study was a randomized controlled trial. Patients with AMI after PCI randomly assigned to a BST group (N = 48) or a control group (N = 48). The BST exercise consists of the sitting and standing forms. The sitting Baduanjin was conducted twice a day in the hospital, for 30 min/session. After the patient was discharged from the hospital, the standing Baduanjin was performed fifth weekly, lasting up to 24-weeks, for 30 min/session. The control group received usual care without Baduanjin. The primary outcomes were the changes of SF-36 subscales. Secondary outcomes included measures of left ventricular ejection fraction(LVEF), N-terminal pro B-type natriuretic peptide (NT-pro-BNP), the Body Mass Index (BMI) and the abdominal circumference. RESULTS Of the 96 participants, 82 total patients completed the entire study. At 12 weeks, Role Physical and Health Transition of SF-36 were significantly different between the two groups, with a difference of 26.12 [95% CI, 11.59 to 40.64] in Role physical and a difference of 15.94 [95% CI, 5.60 to 26.28] in Health Transition (p<0.05). However, there were statistically significant differences in all aspects of SF-36 between the two groups at 24 weeks (p<0.05). The BST also lowered the abdominal circumference and BMI as compared with control group. In the 24-week follow-up, a significant difference was found in the decline of the LVEF in control group (p=0.020),while there was non-significant difference in the BST group (p=0.552). Compared with control group, the BST group reduced 50pg/ml on the NT-Pro-BNP at 24 weeks(p=0.013). The effects of BST exercise were maintained at 24weeks after the intervention. No serious adverse events were observed. CONCLUSIONS The BST appears to improve the quality of life in patients with AMI, with additional benefits of lowered the abdominal circumference and BMI and improved the level of cardiac function. CLINICALTRIAL Clinical Trials.gov:NCT02693795. https://clinicaltrials.gov/ct2/ show/NCT02693795?term=NCT02693795&rank=1.
- 23 August 2019
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe effect of Baduanjin sequential therapy on the quality of life and cardiac function in patients with acute myocardial infarction after percutaneous coronary intervention:A randomized controlled trial (Preprint)
BACKGROUND Acute myocardial infarction (AMI) is a serious type of coronary artery disease (CAD) with the potential for substantial morbidity and mortalit. Percutaneous coronary intervention (PCI) is an effective treatment. However, most patients still suffer from angina pectoris, anxiety, depression and reduced cardiac function after PCI. OBJECTIVE The purpose of this study was to examine the effects of Baduanjin sequential therapy (BST) on the quality of life and cardiac function in patients with AMI after PCI. METHODS The study was a randomized controlled trial. Patients with AMI after PCI randomly assigned to a BST group (N = 48) or a control group (N = 48). The BST exercise consists of the sitting and standing forms. The sitting Baduanjin was conducted twice a day in the hospital, for 30 min/session. After the patient was discharged from the hospital, the standing Baduanjin was performed fifth weekly, lasting up to 24-weeks, for 30 min/session. The control group received usual care without Baduanjin. The primary outcomes were the changes of SF-36 subscales. Secondary outcomes included measures of left ventricular ejection fraction(LVEF), N-terminal pro B-type natriuretic peptide (NT-pro-BNP), the Body Mass Index (BMI) and the abdominal circumference. RESULTS Of the 96 participants, 82 total patients completed the entire study. At 12 weeks, Role Physical and Health Transition of SF-36 were significantly different between the two groups, with a difference of 26.12 [95% CI, 11.59 to 40.64] in Role physical and a difference of 15.94 [95% CI, 5.60 to 26.28] in Health Transition (p<0.05). However, there were statistically significant differences in all aspects of SF-36 between the two groups at 24 weeks (p<0.05). The BST also lowered the abdominal circumference and BMI as compared with control group. In the 24-week follow-up, a significant difference was found in the decline of the LVEF in control group (p=0.020),while there was non-significant difference in the BST group (p=0.552). Compared with control group, the BST group reduced 50pg/ml on the NT-Pro-BNP at 24 weeks(p=0.013). The effects of BST exercise were maintained at 24weeks after the intervention. No serious adverse events were observed. CONCLUSIONS The BST appears to improve the quality of life in patients with AMI, with additional benefits of lowered the abdominal circumference and BMI and improved the level of cardiac function. CLINICALTRIAL Clinical Trials.gov:NCT02693795. https://clinicaltrials.gov/ct2/ show/NCT02693795?term=NCT02693795&rank=1.